By. Valeria Santini, MDDate: 12/13/2023At the ASH 2023 symposium, Valeria Santini, MD, a distinguished medical doctor and associate professor of hematology from the University of Florence Medical School in Italy, engaged the audience in a discussion about the Phase 3 Medalist study.Dr. Santini commenced her presentation by providing a comprehensive overview of the Medalist trial initiated in 2016. This clinical investigation focused on assessing the response to Luspatercept, an active erythroid maturation agent. The study specifically targeted lower-risk myelodysplastic syndromes (MDS) patients with transfusion dependence who were refractory or ineligible for conventional erythropoietic stimulating agents.The trial involved the administration of…
Author: admin
By. Robert Rifkin, MDDate: 12/13/2023 Robert Rifkin, MD, a medical oncologist and hematologist at SCRI in Rocky Mountain Cancer Centers, part of the U.S. Oncology Network, for a discussion about a phase two study on the outpatient administration of Teclistamab, a bispecific antibody targeting BCMA in patients with multiple myeloma. Dr. Rifkin explains that the study aims to bring new classes of myeloma drugs into the clinic and community more practically. Teclistamab, being the first bispecific antibody released for multiple myeloma, initially mandated hospitalization due to concerns about cytokine release syndrome (CRS) and neurologic dysfunction. The study seeks to introduce…
By. Halle Moore, MD Date. 12/13/2023 Halle Moore, MD, the Medical Doctor and Director of Breast Medical Oncology and Co-Director for the Comprehensive Breast Cancer Program at Cleveland Clinic, shares insights into a study focusing on fertility preservation and assisted reproductive technologies in breast cancer patients who interrupt endocrine therapy to attempt pregnancy.Dr. Moore discusses the eligibility criteria for women in the study, emphasizing factors such as age, stage of breast cancer, and duration of adjuvant endocrine therapy. The study, aimed at assessing the short-term safety of interrupting endocrine therapy for pregnancy, explores outcomes related to assisted reproductive technology and…
By. Saranya Chumsri, MD Date: 12/12/2023 Saranya Chumsri, MD, an expert in the field of triple-negative breast cancer (TNBC), will provide answers to questions during the interview. The discussion will cover the significance of evaluating immune landscapes in TNBC, the use of technologies such as NanoString IO360 and Digital Spatial Profiling, the association between immune-related proteins and different landscapes, the exploration of the PI3K-Akt signaling pathway, and the implications of single-cell sequencing findings on targeted therapies. Dr. Chumsri’s insights aim to offer objective perspectives on understanding TNBC and guiding potential treatment strategies.
Amidst the atmosphere of SABCS 2023, and at the center was Yara Abdou, MD, a medical oncologist from the University of North Carolina Chapel Hill. Graciously taking the time to engage in conversation, Allen extended his gratitude to Dr. Abdou for joining the discussion.In their exchange, the focus shifted to the intricate realm of medical practice, specifically exploring the practice patterns associated with the sequential use of antibody drug conjugates after antibody drugs. Dr. Yara Abdou delved into the complexities of this topic, shedding light on the challenges faced by providers in sequencing these drugs due to the yet-to-be-fully-understood efficacy…
By: Ibrahim Aldoss, MD – City of HopeDate: 12/11/2023Revumenib Monotherapy in KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study
At ASH 2023, there is a discussion with Dr. Davide Matino, Assistant Professor of Medicine at McMaster University, shedding light on the groundbreaking findings from the phase three basis trial concerning the anti-tissue factor pathway inhibitor, Marstacimab. The conversation delves into the study’s design and outcomes, focusing on a cohort of patients with severe hemophilia A or moderately severe to severe hemophilia B without inhibitors.Dr. Matino provides a comprehensive overview of the study, detailing the observational phase, loading doses, and subsequent treatment phases involving Marstacimab. The emphasis is on the subcutaneous administration of the drug, representing a pivotal advancement in the…
Allen Wilbanks stands at the forefront of SABCS 2023, the setting for a conversation with Thomas Budd, MD, a medical doctor and oncologist from the Cleveland Clinic Cancer Center. In this discussion, Allen introduces the focus—the Phase 1 trial of the Alpha-Lactalbumin vaccine in high-risk operable triple-negative breast cancer (TNBC) patients and those with a genetic predisposition to TNBC.Dr. Budd elaborates on the primary objectives of the trial, emphasizing the critical role of determining the appropriate vaccine dosage for future applications. The trial evaluates toxicity, primarily manifested as local injection site reactions, and measures immune responses through Alispot assays. The…
Allen Wilbanks finds himself at SABCS 2023, where he engages in a discussion with Dr. Adam Brufsky, a medical doctor, professor of medicine, and associate chief division hematology, oncology, and co-director of the Comprehensive Breast Cancer Center at the University of Pittsburgh.In the interview, Allen queries Dr. Brufsky about the real-world effectiveness of Palbociclib, or palbociclib, in combination with aromatase inhibitors for metastatic breast cancer patients with cardiovascular disease. Dr. Brufsky delves into the key findings of the study, highlighting the analysis of patients who were not part of clinical trials, and emphasizing the significance of real-world evidence.The study, known…
Wassim Mchayleh, MD, an expert in oncology, participated in the SABCS 2023 conference, offering insights into the latest developments in breast cancer research.Regarding groundbreaking findings or emerging trends at SABCS 2023, Dr. Mchayleh discussed studies potentially impacting clinical practices in breast cancer management, including novel therapeutic approaches and advancements in targeted therapies.In the area of cutting-edge technologies, Dr. Mchayleh addressed abstracts on precision medicine, genomics, and other innovative approaches in breast cancer research.The conversation then turned to a special feature on Minimal Residual Disease (MRD) testing. Dr. Mchayleh answered questions on the utility of MRD testing and its significance in…
Jeff Sharman, MD, a medical oncologist at the Willamette Ballet Cancer Institute and Research Center, also serving as the Medical Director of Hematology Research at the Sarah Cannon Research Institute.Phase 3 Elevate TN trial, a focus of Sharman’s work. The trial, designed for previously untreated chronic lymphocytic leukemia patients, included three arms: a control arm with Obinutuzumab chlorambucil, and two experimental arms with either acalabrutinib monotherapy or a combination of acalabrutinib with obinutuzumab. Sharman reveals that the study resulted in FDA approval for acalabrutinib in previously untreated patients.During the discussion, Sharman unveils key findings from the six-year follow-up study. Notably,…
Allen Wilbanks stood alongside Alina Hamilton, PhD, at the SABCS 2023 event, where they delved into groundbreaking research on breast cancer immunotherapy. Alina Hamilton, a postdoctoral research associate in the cancer control education program at the Lineberger Comprehensive Cancer Center, University of North Carolina Chapel Hill, shared insights on her work.Motivated by the alarming 41 percent higher breast cancer mortality rate among black women, Hamilton explored Survivin as a potential immunotherapy target. Survivin, a protein in the inhibitor of the apoptosis pathway, showed associations with aggressive tumor features, especially in breast cancer. Despite smaller and less diverse previous studies, Hamilton…
By: Melinda Telli, MD, Date: 12/9/2023 At the SABCS 2023 conference, we had the privilege of interviewing Melinda Telli, MD, a medical doctor, associate professor of medicine at Stanford University School of Medicine, and the director of the breast cancer program at Stanford Cancer Institute. Dr. Telli shared insights on recent advances in triple-negative breast cancer (TNBC) during a session she presided over.In the interview, Dr. Telli discussed progress in TNBC treatment and management, emphasizing that breakthroughs have occurred in the past five years. She traced the evolution of TNBC understanding since its first description in 2005, highlighting milestones such…
By: Hope Rugo, MD Date: 12/9/2023 At the SABCS 2023 conference, medical oncologist Hope Rugo from the University of California, San Francisco, engaged in a comprehensive discussion with interviewer Allen Wilbanks about the Keylink 009 study. Hope Rugo shared insights into the randomized open-label phase 2 trial, which aimed to assess the efficacy of the combination of Pembrolizumab and Olaparib as maintenance therapy for patients with triple-negative breast cancer (TNBC) receiving chemotherapy and Pembrolizumab.The trial enrolled patients with metastatic or locally advanced unresectable TNBC who had not undergone prior treatment in the metastatic setting. The treatment protocol involved induction chemotherapy…
By: Yara Abdou, MD, Date. 12/08/2023 At SABCS 2023, Yara Abdou, MD, a medical oncologist from the University of North Carolina Chapel Hill, discusses a phase one clinical trial titled “Translational Insights from a Phase One: First in Human Clinical Trial of the Anti-HER2.”In this trial, the focus is on CAR macrophages, a therapy for solid tumors expressing HER2, with 57 percent being breast cancer patients. Dr. Abdou explains the process: patients undergo leukophoresis to obtain monocytes, differentiated into macrophages, and transduced with an adenoviral vector to polarize the macrophage into an M1 phenotype. The CAR gene is encoded, and…
By: Hatem Azim, MD Date. 12/08/2023At SABCS 2023, a discussion on fertility preservation and assisted reproductive technologies in breast cancer patients interrupting endocrine therapy to attempt pregnancy. The speaker for this session was Hatem Azim, MD, a medical doctor, medical oncologist, and adjunct professor at the School of Medicine of the Monterey Institute of Technology. Additionally, Hatem Azim holds the position of Senior Oncology Faculty at the College of the European School of Oncology.Opening the conversation, Allen Wilbanks acknowledged Hatem Azim’s expertise and expressed gratitude for his presence in the discussion. Hatem Azim delved into the key findings from the positive trial…
Treatment differences by race and age in metastatic hormone receptor-positive/HER2- with Yara Abdour, MDTranscript (spelling not corrected)Yara Abdou, MD – Treatment differences by race and age in metastatic hormone receptor-positive/HER2- with Yara Abdour, MD 
Allen Wilbanks: [00:00:00] Okay, we’re here at S. A. B. C. S. 2023 and we’re lucky enough to have Dr Yara Abdu, a medical oncologist at the University of North Carolina Chapel Hill. Thank you so much for sitting down with us. 
Yara Abdou, MD: Absolutely. Thank you for having me. So 
Allen Wilbanks: today we’re gonna be discussing treatment differences by race and age and…
By: Julie Lang, MD Date. 12/07/2023Julie Lang, MD, a medical professional known for expertise in breast cancer research, has developed the Mechanical Conditioning Score (MCS), a test for identifying early-stage breast cancer patients with potential poor prognoses.The MCS evaluates mechanical factors and markers in breast tissues, such as tissue stiffness, cellular alignment, and extracellular matrix composition. It aids in predicting patient prognoses and informing treatment decisions.In terms of antifibrotic therapy, Lang’s research identifies how the MCS determines patients likely to respond to such interventions. By pinpointing individuals with increased tissue stiffness and fibrotic changes, the MCS becomes a tool for…
By. Terry Mamounas Date: 12/07/2023In a collaborative study between NVP and RT, led by oncologist Terry Mamounas, MD, the NSABP B-51/RTOG 1304 trial aimed to assess the role of local-regional radiotherapy in patients with initially positive axillary nodes that turned negative after neoadjuvant chemotherapy.The study objectives were to evaluate the necessity and potential benefits of local-regional radiotherapy in this specific patient population, focusing on the impact on invasive breast cancer recurrence-free interval (IBCF RFI). The study design incorporated a randomized comparison between patients receiving local-regional radiotherapy and those not, ensuring a thorough assessment of treatment effectiveness.Patient characteristics and demographics in…
By. Joanne Kotsopoulos, MD, Date: 12/07/2023 At the SABCS 2023 conference, Joanne Kotsopoulos, MD, a researcher from the Women’s College Research Institute in Toronto, engaged in a discussion with Allen Wilbanks. The focus of their conversation was on the cancer risk associated with exogenous hormone use in women with inherited BRCA1 or BRCA2 mutations, a topic Kotsopoulos has extensively researched.In her presentation, Kotsopoulos provided an overview of the complex relationship between exogenous hormones, such as oral contraceptives and hormone replacement therapy, and the risk of breast and ovarian cancer in mutation carriers. She delved into the existing evidence, including both established…
By: Virginia Kaklamani, MD Date: 12/8/2023 Virginia Kaklamani, MD, a professor of medicine in the Division of Hematology and Oncology at UT Health San Antonio and the leader of the breast cancer program at UT Health San Antonio MD Anderson Cancer Center, engaged in a conversation at SABCS 2023. Kaklamani shared insights on the highlights and trends observed during the event. Discussing various themes, the conference explored prevention strategies for breast cancer on chemopreventive strategies and estradiol level assessments to identify high-risk individuals. The discussions extended to advancements in early-stage treatment, exploring topics such as radiation therapy necessity and axillary…
By. Kellogg Parsons, MD Date: 12/07/2023 Kellogg Parsons, MD, a medical doctor and Vice President of Clinical Development at Embrace Therapeutics, joins him. As the interview unfolds, Dr. Parsons shares insights into the preclinical data of MBRC 101, a drug targeting the receptor tyrosine kinase.In their discussion, Dr. Parsons discusses the applications of MBRC 101 in advanced metastatic solid tumors, particularly in breast cancer subtypes like triple-negative and H.R. positive HER2-negative. The uniqueness of EphA5, highly expressed in cancer cells with minimal presence in normal tissues, makes it a prospect for targeted cancer therapy.Moving on to the pharmacokinetic aspects, Dr. Parsons…
By. Ruth O’Regan MD Date: 12/07/2023In an interview, Ruth O’Regan MD addresses questions related to the use of CDK4/6 inhibitors in the treatment of metastatic ER+ breast cancer. As an authority in the field, Dr. O’Regan provides perspectives on the ongoing debate regarding the similarities and differences among these inhibitors and their impact on patient outcomes.The first question explores the debate on whether CDK4/6 inhibitors exhibit distinct characteristics in terms of efficacy, given their known improvements in progression-free survival and overall survival. Dr. O’Regan discusses the nuances of this debate, providing an understanding of the variations among these inhibitors and their…
By. Neil Carleton, MD Date. 12/07/2023 In the interview with Neil Carleton, MD, the discussion revolved around the age-related remodeling of the systemic and breast microenvironment and its implications for promoting a tumor-permissive environment in ER+ breast cancer, as presented in recent research. Dr. Carleton expertly elaborated on the significance of factors beyond accumulating mutations, such as changes in estrogen disposition, inflammation, and immune contexture, in contributing to the age-related nature of ER+ breast cancer. He emphasized the potential impact of understanding these factors on future approaches to cancer prevention and treatment in older women.As the conversation delved deeper, Dr. Carleton…
By: Carol Fabian, MD Date. 12/07/2023 In an interview, Carol Fabian, MD, an expert in breast cancer research and prevention, will discuss critical aspects of breast cancer risk assessment and prevention. She will address the utility of polygenic risk scores, explaining how they complement imaging and influence decisions regarding risk reduction therapy.Dr. Fabian will provide information on hormone replacement and alternatives for women at moderate to high risk of developing breast cancer. She will discuss safe alternatives considered in this context, focusing on choices aligned with patient safety and well-being.The conversation will touch upon the presentation by Dr. Joanne Kotsopoulos, focusing…
By: Joyti Bajpai, MD Date: 12/07/2023 In a forthcoming interview, Jyoti Bajpai, MD, a renowned expert in the field, will explore the nuances of the Olanzapine-3 study, focusing on the comparison between low-dose and standard-dose Olanzapine in triple antiemetic therapy for highly emetogenic chemotherapy in solid tumor patients. Dr. Bajpai will provide insight into the significance of the Olanzapine study, shedding light on the impact of the combination therapy involving Olanzapine on complete response rates in patients undergoing highly emetogenic chemotherapy regimens. The interview will explore the potential breakthroughs this study presents for improving patient outcomes. The discussion will pivot…
By. Anjali Advani, MD Date. 12/06/2023 In this conversation on OncologyTube, viewers can explore the SWOG 18 clinical trial with host Allen Wilbanks and Dr. Anjali Advani, a medical oncologist and professor at the Cleveland Clinic. The discussion centers on the long-term follow-up data of combining dasatinib, prednisone, and blinatumomab for the treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) in older patients.Dr. Advani, the director of the inpatient leukemia program at the Cleveland Clinic, provides insights into the eligibility criteria for the study, specifically focusing on older patients with Ph+ ALL. The conversation delves into the treatment protocol’s…
By: Anjali Advani, MD Date: 12/06/2023 Dive into this insightful conversation with Dr. Anjali Advani, a distinguished medical oncologist and professor specializing in hemologic oncology and blood disorders at the Cleveland Clinic. Dr. Advani serves as the director of the inpatient leukemia program at the Tosset Cancer Institute. The discussion centers around groundbreaking research on Brexucabtagene Autoleucel therapy in adults with relapse refractory cells.Opening the conversation, Allen introduces Dr. Advani and expresses gratitude for her presence on the show. The dialogue delves into the significant response rates observed in adults treated with Brexucabtagene Autoleucel therapy. Dr. Advani emphasizes the real-world…
By. Fairooz F. Kabbinavar, MD, FACP​ Date. 12/06/2023 Fairooz F. Kabbinavar, MD, FACP, a medical oncologist with a background in academia and drug development, began his journey at Harvard in Boston, culminating in a hematology oncology fellowship at UCLA. During his 25-year tenure at UCLA, he rose to the rank of full professor of medicine and medical oncology, receiving an endowed chair for his contributions to clinical cancer research. Dr. Kabbinavar’s commitment to advancing cancer therapeutics, particularly in new drug development, led him to join Genentech and subsequently other biotech companies. His pivotal role in the development and approval of…
By. Josina Reddy, MDDate. 11/24/2023Today, the focus is on the ALINA trial, a phase three study comparing Alectinib versus chemotherapy as adjuvant therapy for patients with stage 1B to 3A ALK-positive non-small cell lung cancer. Presented in 2023, the trial results are discussed by Josina Reddy, MD. The significance of the phase 3 ALINA results lies in the 76% reduction in the risk of disease recurrence or death with Alectinib compared to platinum-based chemotherapy in ALK-positive early-stage non-small cell lung cancer.Josina Reddy, MD, explains that the ALINA trial enrolled patients with early-stage lung cancer that could be surgically removed, specifically…
By. Allen WilbanksDate. 11/23/2023Lot Aronson, MD, a medical doctor and researcher from the Department of Gynecologic Oncology in the Netherlands Cancer Institute, engaged in a discussion with Allen Wilbanks of Oncology Tube. The focus was the updated 10-year survival analysis from the OVHIPEC-1 trial, exploring the effects of cytoreductive surgery with or without hypothermic intraperitoneal chemotherapy (HIPEC) in patients with advanced ovarian cancer.Aronson initiated the conversation by providing an overview of the trial’s design, emphasizing its initiation in 2006 and subsequent publication in 2018. The OVHIPEC-1 trial, an open-label, randomized controlled phase three study, recruited patients from specialized centers in…
By. Anusha Kalbasi, MDDate. 11/22/2023In a recent discussion on adoptive T cell therapies for solid tumors, Anusha Kalbasi, MD, provided a comprehensive analysis of various modalities, shedding light on their challenges and potential breakthroughs. Kalbasi began by delving into the realm of tilt therapy, a longstanding approach for melanoma patients. Over the last decade or two, industry interest has surged, revealing response rates of 30 to 50 percent in heavily pretreated melanoma patients. The comparison with immune checkpoint blockade, particularly ipilimumab, has demonstrated promising data on tilt therapy’s longer progression-free survival.The conversation then shifted to TCR-engineered therapy, where Kalbasi elucidated…
By. Bridget Keenan, MDDate. 11/22/2023Bridget Keenan, MD, discusses the tumor microenvironment (TME) and its crucial role in cancer immunotherapy responses. Dr. Keenan notes that effector T cells align with positive outcomes, while suppressive myeloid cells and cytokine signals within the TME often signify a less favorable prognosis and resistance to immunotherapy.During the presentation, Dr. Keenan explores targeting the TME through immunotherapies, focusing on tumor metabolism and immunosuppressive myeloid cells. Despite various drugs aiming at the TME, no standout winner has emerged, prompting Dr. Keenan to discuss potential strategies for more effective interventions.She highlights exploring metabolic byproducts with higher concentrations in…
By. Bartosz Chmielowski, MD PhDDate: 11/22/2023In this presentation, Bartosz Chmielowski, MD PhD, discusses advancements in cancer therapy, focusing on approaches utilizing herpes virus-based treatments. The spotlight is on T VEC, the pioneering herpes virus therapy for cancer patients. The approval of this therapy was based on the durability of responses observed during clinical trials, demonstrating a heightened response rate compared to G-M-C-S-F injections alone.Bartosz Chmielowski, MD PhD, emphasizes the specificity of T VEC, clarifying that it is tailored for patients with easily injectable diseases, limited to skin lesions or palpable lymph nodes. The therapy showcased a borderline improvement in overall…
By. Anna M. Wu, MD, PhDDate. 11/21/2023Anna M. Wu, MD, PhD, discussed the use of immunotherapy in patients who underwent melanoma resection and reviewed drug development strategies in this field. She traced the progression from treating advanced, unresectable cases to improved outcomes in stage three and node-negative diseases.Wu highlighted the shift from post-surgery to pre-surgery immunotherapy, citing the S1801 clinical trial’s significant improvement in event-free survival with pre-surgery treatment. She discussed ongoing trials and emerging data on effective combinations, including early outcomes of a cancer vaccine in melanoma.Regarding the future of immunotherapy, Wu mentioned combining drugs like nivolumab and melatomab…
By. Arta Monjazeb, MDDate: 11/21/2023Arta Monir Monjazeb, MD, explores cancer immunotherapy with a detailed discussion on the immune response, radiation’s role, and the challenges of combining radiotherapy with immune checkpoint inhibitors (ICI). As a prominent figure in the field, Dr. Monjazeb brings forth insights that bridge clinical practice and research.In an exploration of the immune response, Dr. Monjazeb emphasizes the role of antigen-presenting cells in transitioning from innate to adaptive immunity. He discusses the intricate relationship between radiation and the immune system, emphasizing the importance of immunogenic cell death and the subsequent activation of T cells.Touching upon disparities among cancer…
By. Greg Daniels, MD Date: 11/21/2023 In this discussion, Dr. Greg Daniels, a physician in the field of solid organ transplantation, provides information on the complexities faced by transplant patients, particularly those who have undergone kidney or heart transplants. With experience, Dr. Daniels emphasizes the role of immune suppressive drugs in maintaining the viability of transplanted organs, preventing rejection by the recipient’s body.Dr. Daniels elucidates the various immune suppressive agents used, highlighting the differences among them. Notably, he underscores the risk of cancer, particularly skin cancers such as cutaneous squamous cell carcinoma, as a concern for transplant patients. The physician…
By. Katy Tsai, MDDate: 11/21/2023Katy Tsai, MD, discusses the progress in cancer survivorship on a national scale, citing data from the American Cancer Society projecting a significant increase in the number of cancer survivors in the United States over the next decade. Katy Tsai, specializing in treating advanced melanoma skin cancer patients, reflects on advancements in melanoma survivorship with the introduction of immune checkpoint inhibitors.In her dialogue, Katy Tsai delves into the historical context, emphasizing the shift from dire prognoses for metastatic melanoma patients to outcomes with contemporary treatments. She specifically mentions the success of combination immune checkpoint inhibitor blockade,…
Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Stephen Liu gives an overview of treatment options for patients with NTRK+ NSCLC and what some side effects may be. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.
Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Stephen Liu discusses recent developments in RET+ NSCLC treatment, including next-generation RET TKIs. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.
Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Stephen Liu compares selpercatinib and pralsetinib as treatment options for patients with RET+ disease. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.
Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Stephen Liu discusses Pralsetinib as a treatment option for RET+ disease. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.
Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Stephen Liu discusses Selpercatinib as a treatment option for RET+ disease. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.
Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Stephen Liu discusses how RET fusions are detected, and discusses methods of treatment, including Selpercatinib and Pralsetinib. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.
Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Misako Nagasaka details treatment options and study data for patients with ROS1+ NSCLC. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.
Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Misako Nagasaka gives an in-depth discussion on ALK+ NSCLC, from possible treatment options to study data. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.
Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, the panel discusses the importance of knowing genetic testing results regardless of PD-L1 level. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.
Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, the panel discusses if there’s a reason some patients can remain on TKIs for extended time without developing resistance. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.
Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, the panel discusses methods of delivering SBRT, including CyberKnife. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.
Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, the panel discusses current understanding of what can cause lung cancer, and prevention methods. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.